These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27648101)

  • 1. Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.
    Oral EA
    Drugs Context; 2016; 5():212299. PubMed ID: 27648101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
    Cavaiola TS; Pettus J
    Diabetes Metab Syndr Obes; 2018; 11():133-148. PubMed ID: 29695924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice.
    Fitchett DH
    Eur Endocrinol; 2018 Sep; 14(2):40-49. PubMed ID: 30349593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control.
    Satoh H
    Diabetol Int; 2018 Oct; 9(4):212-214. PubMed ID: 30603370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.
    Gallwitz B
    Eur Endocrinol; 2018 Apr; 14(1):17-23. PubMed ID: 29922347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
    Levine MJ
    Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
    Marx N; McGuire DK
    Eur Heart J; 2016 Nov; 37(42):3192-3200. PubMed ID: 27153861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
    Pancholia AK
    Indian Heart J; 2018; 70(6):915-921. PubMed ID: 30580866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review.
    Rastogi A; Bhansali A
    Diabetes Ther; 2017 Dec; 8(6):1245-1251. PubMed ID: 29076040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibition and heart failure-current concepts.
    Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
    Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
    Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
    Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.